Expert Early-Phase Strategy
Investors and licensing partners want an early-phase plan that answers the hard questions up front: how quickly the first patient can be dosed, what it will cost, and what the data will support next. Avance Clinical’s protocol design and regulatory readiness are built to answer them before the first patient is dosed, so you walk into a partnering meeting with fewer open questions. Our ClinicReady program adds expert teams who guide your project through the early drug development phases, supporting a rapid, efficient trial start.
A Faster, More Capital-Efficient Route to Clinical Data in Australia
For most early-phase trials, Australia removes the IND step, which can take up to 12 months out of regulatory timelines, and study start-up runs 5–6 weeks from final protocol to approval. Biotechs running early-phase trials in Australia can also access R&D rebates of up to 43.5% on eligible spend, stretching runway further. Data generated there is accepted by the FDA, EMA, and other major regulators, so the dataset you bring to your next investor or partner doesn’t need to be repeated.
A Global Development Path That Scales With You
Avance Clinical’s GlobalReady program takes biotechs from early-phase trials in Australia into multi-regional studies across Asia-Pacific, China, North America, and Europe with one CRO, giving partners a development plan that already crosses borders.
The GlobalReady Site Partnership Network, with thousands of clinical sites, sits alongside a strong operational presence in Australia, New Zealand, Asia-Pacific, North America, and Europe, and dedicated in-house teams that support regulatory compliance and efficient project delivery.
This integrated approach is designed to support global acceptance of clinical data, faster approvals, and lower costs, so the team and data standards a licensing partner reviews today are the ones that carry the program forward.
Therapeutic Depth Behind the Science
Early-phase work is backed by therapeutic Centers of Excellence in Oncology, CNS, and Renal & Cardiometabolic, plus experience across more than 250 therapeutic indications, depth that partners and investors weigh alongside the molecule.
